Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 1/20 | 0.59 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MC4R | P32245 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | MC3R | P41968 | 1/20 | 0.34 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3174330 | 0.85 | NNMT (0.67) | NNMTPARP1KMT2APIM1LMNA | |
| SCHEMBL3889503 | 0.79 | KDM4E (0.42) | NNMTKMT2ALMNATDP1APLNR | |
| SCHEMBL4927935 | 0.79 | KCNJ1 (0.44) | NNMTP2RX7KMT2AAPLNR | |
| SCHEMBL18735817 | 0.77 | NOS1 (0.36) | NNMTLMNAAPLNR | |
| SCHEMBL30252481 | 0.77 | P2RX7 (0.59) | NNMTP2RX7KMT2AADORA3POLB | |
| SCHEMBL280264 | 0.77 | P2RX7 (0.59) | NNMTP2RX7KMT2AADORA3POLB | |
| SCHEMBL3174349 | 0.76 | NNMT (0.57) | NNMTPARP1KMT2APIM1LMNA | |
| SCHEMBL30509853 | 0.74 | NNMT (0.55) | NNMTPARP1KMT2APIM1LMNA | |
| SCHEMBL3153355 | 0.74 | NNMT (0.55) | NNMTGABRA1KMT2APIM1LMNA | |
| SCHEMBL6873451 | 0.74 | APLNR (0.36) | NNMTKMT2ALMNAAPLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10383871-B2 | Azetidine derivatives | VERNALIS (R&D) LTD. (GB) | 2019-08-20 | — | — | US | claimed |
| US-20170196864-A1 | Azetidine Derivatives | VERNALIS DEVELOPMENT LIMITED (GB) | 2017-07-13 | — | — | US | claimed |
| US-9475800-B2 | Azetidine derivatives | VERNALIS (R&D) LTD. (GB) | 2016-10-25 | — | — | US | claimed |
| US-9440956-B2 | Indole, indazole and benzimidazole arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2016-09-13 | — | — | US | claimed |
| US-20150183769-A1 | Azetidine Derivatives | VERNALIS DEVELOPMENT LIMITED (GB) | 2015-07-02 | — | — | US | claimed |
| US-9006269-B2 | Azetidine derivatives | VERNALIS (R&D) LTD. (GB) | 2015-04-14 | — | — | US | claimed |
| EP-2445897-B1 | NOVEL INDAZOLE ARYLAMIDES AS P2X3 AND/OR P2X2/3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2014-03-19 | — | — | EP | claimed |
| US-20130331371-A1 | Azetidine Derivatives | VERNALIS (R&D) LTD. (GB) | 2013-12-12 | — | — | US | claimed |
| US-20130267529-A1 | INDOLE, INDAZOLE AND BENZIMIDAZOLE ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | DILLON MICHAEL PATRICK (US) | 2013-10-10 | — | — | US | claimed |
| US-8476457-B2 | Indole, indazole and benzimidazole arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2013-07-02 | — | — | US | claimed |
| JP-2007500717-A | — | — | 2007-01-18 | — | — | JP | claimed |
| WO-2007005763-A2 | COMBINATION OF A RENIN INHIBITOR AND AN INSULIN SECRETION ENHANCER OR AN INSULIN SENSITIZER | NOVARTIS AG (CH) | 2007-01-11 | — | — | WO | claimed |
| WO-2006086445-A2 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2006-08-17 | — | — | WO | claimed |
| US-20060135589-A1 | 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors | ASTEX TECHNOLOGY, INC. (GB) | 2006-06-22 | — | — | US | claimed |
| EP-1648874-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-04-26 | — | — | EP | claimed |
| JP-2006500348-A | — | — | 2006-01-05 | — | — | JP | claimed |
| EP-1534685-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS | Astex Technology Limited (GB) | 2005-06-01 | — | — | EP | claimed |
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2005-03-24 | — | — | US | claimed |
| WO-2005011655-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | claimed |
| WO-2004014864-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS | ASTEX TECHNOLOGY LIMITED (GB) | 2004-02-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | PRDX5, SNRPD3, SNRPD2 | NNMT 1951/4885GABRA1 4524/4885PARP1 818/4885 |
| US-20130331371-A1 | Azetidine Derivatives | FAAH2, FAAH, APEH | NNMT 3139/4885GABRA1 361/4885PARP1 434/4885 |
| US-20150183769-A1 | Azetidine Derivatives | FAAH2, FAAH, APEH | NNMT 3139/4885GABRA1 361/4885PARP1 434/4885 |
| US-20170196864-A1 | Azetidine Derivatives | FAAH2, FAAH, APEH | NNMT 3113/4885GABRA1 345/4885PARP1 433/4885 |
| US-10383871-B2 | Azetidine derivatives | FAAH2, FAAH, APEH | NNMT 3113/4885GABRA1 345/4885PARP1 433/4885 |
| US-20060135589-A1 | 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors | CCNC, CDK1, CDK7 | NNMT 338/4885GABRA1 2412/4885PARP1 2337/4885 |
| US-20130267529-A1 | INDOLE, INDAZOLE AND BENZIMIDAZOLE ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX5 | NNMT 3293/4885GABRA1 569/4885PARP1 2133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.